FDA approves ALK's house dust mite tablet for teens
Following FDA clearance, the Odactra tablet will be available for an even broader patient population. The treatment is already approved for adults.
by marketwire, translated by daniel pedersen
The label of allergy group ALK’s Odactra, a tablet treatment for house dust mite allergies, has been extended to include teens between 12 and 17 years old in the US.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK loses R&D exec, finds Novo Nordisk replacement
For subscribers
Allergy Therapeutics appoints interim CFO
For subscribers
